Naoshi Nishida

机构：Kindai University Hospital, Japan Society of Ultrasonics in Medicine, Denka (Japan), Kindai University · ORCID：0000-0002-9111-5668

发表论文 526 篇 · 总被引 9873 次 · h-index 56

代表论文

• Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study (2025 · Journal of Gastroenterology · 被引 12)
• Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway (2025 · Clinical and Molecular Hepatology · 被引 11)
• Advancements in Artificial Intelligence-Enhanced Imaging Diagnostics for the Management of Liver Disease—Applications and Challenges in Personalized Care (2024 · Bioengineering · 被引 11)
• Biomarkers and Management of Cholangiocarcinoma: Unveiling New Horizons for Precision Therapy (2025 · Cancers · 被引 9)
• Lenvatinib versus Sorafenib Second-Line Therapy in Patients with Hepatocellular Carcinoma Progressed to Atezolizumab plus Bevacizumab: A Retrospective Real-World Study (2024 · Oncology · 被引 9)
• ALBI Grade Enables Risk Stratification for Bleeding Events and Refines Prognostic Prediction in Advanced HCC Following Atezolizumab and Bevacizumab (2025 · Journal of Hepatocellular Carcinoma · 被引 6)